AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06358911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manufacturer's desensitizing agent, Ultra EZ
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes.
Study NCT06358911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI paste plus, desensitizing agent
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes.
Study NCT06358911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and F (ReminPro), desensitizing agent
Description: Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes
Study NCT05826015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV over 3 hours
Study NCT05826015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: IV over 60 minutes
Study NCT06056622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combined Exercises
Description: The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces.
Study NCT06056622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Exercise
Description: Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
Study NCT04975750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving intervention
Description: The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
Study NCT04975750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
Study NCT04811612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Warmed heel stick
Description: One heel will be warmed before sampling with the other heel will not be warmed
Study NCT05230342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A package containing a mix of functional foods
Description: Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
Study NCT05230342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ingredient group
Description: The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
Study NCT05702242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD removal with no visible strings
Description: Removal with either alligator forceps or MVA
Study NCT05702242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alligator forceps
Description: IUD removal with alligator forceps
Study NCT05702242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspirator
Description: IUD removal with MVA
Study NCT05222035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
Study NCT05222035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
Study NCT05222035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
Study NCT05266014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinlarebant
Description: Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months.
Study NCT04902417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy Foods (Yoghurt, Cheese, Milk)
Description: Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
Study NCT05401110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Study NCT05401110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab
Description: Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Study NCT05523011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exosome ointment
Description: 100 µg MSC exosomes/g ointment
Study NCT05070988 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
Study NCT05723913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: A package containing a mix of functional foods
Description: Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
Study NCT04828226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
Study NCT04828226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
Study NCT06503783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT05710991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Workshop
Description: Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise
Study NCT05710991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia Workshop
Description: The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
Study NCT06648070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular reeducation technique
Description: 5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
Study NCT06648070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
Study NCT05169437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Eligible participants will receive daily dosing of Niraparib.
Study NCT04863781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile cognitive-behavioral stress management intervention
Description: Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
Study NCT04863781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
Study NCT05931627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients undergoing ACL reconstruction with or without a tourniquet
Description: Patients undergoing ACL reconstruction with or without a tourniquet
Study NCT06347029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling
Study NCT06347029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Study NCT05403060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIADA: Alimentación, Adolescencia y Ambiente
Description: The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
Study NCT05024422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
Study NCT05024422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: Administration of Pyridoxine (200 mg X 3 per day for a week)
Study NCT04853147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
Study NCT04853147 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: palonosetron, dexamethasone, and 0.9% NaCl
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
Study NCT05068674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells
Description: 50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
Study NCT05068674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells
Description: 150M cells delivered in a dose of 15M cells per injection over 10 injections
Study NCT05068674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Description: 300M cells delivered in a dose of 30M per injection over 10 injections
Study NCT04732429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST5040
Description: Liquid solution
Study NCT04732429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liquid solution
Study NCT05893680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group to play online games
Description: Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
Study NCT05893680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group that received cold application
Description: Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
Study NCT05893680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)
Description: The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
Study NCT05893680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group that played an online game and received cold application at the same time
Description: To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
Study NCT04904081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
Study NCT05191641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized nursing care
Description: Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
Study NCT05929508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
Study NCT05929508 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ischemic Preconditioning
Description: A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
Study NCT04826328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX301
Description: FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
Study NCT04826328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single peripheral nerve injection
Study NCT06347029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow mediated dilatation test
Description: The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
Study NCT05460429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
Study NCT05381181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
Study NCT05144438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Toxseek test
Description: Hair taking
Study NCT05441371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste; Paradontax
Description: Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
Study NCT05441371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste; Paradontax
Description: Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
Study NCT05889585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaire
Description: EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
Study NCT04686279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study NCT04705363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectal Features Varied
Description: Participants will randomized to interact with a VHA that speaks either Standardized American English, a low level of African American English, or a high level of African American English
Study NCT04705363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Intervention
Description: Participants will randomized to either receive a video introduction from the voice actor or receive no introduction
Study NCT04705363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VHA with no voice
Description: virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
Study NCT06529731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Description: ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.